Novo Nordisk’s Profit Surge Masks the Real Story: A Pipeline Pivot Underway

The Danish drugmaker has delivered a first-quarter earnings beat that caught the market off guard, but the real drama is unfolding behind the scenes in its research labs. Novo Nordisk’s decision to scrap a high-profile combination therapy has investors questioning whether the company’s next act is already being rewritten.

Adjusted operating profit for the three months through March came in at 32.86 billion Danish kroner, comfortably ahead of the 28.74 billion kroner consensus estimate. The bottom line got a boost from a one-off US provision and rapid uptake of newer product formats. On an unadjusted basis, revenue hit 96.82 billion kroner, while net profit surged 67 percent to 48.56 billion kroner.

Management responded by nudging its full-year guidance higher. The company now expects adjusted sales and operating profit to decline between 4 and 12 percent in 2026, an improvement from the prior range of 5 to 13 percent. Morgan Stanley analysts described the revised outlook as conservative.

The CagriSema Shock

The bombshell landed in the pipeline update. Novo Nordisk is pulling the plug on the injectable CagriSema combination of semaglutide and cagrilintide, citing “portfolio considerations.” The decision raises questions about the company’s next-generation obesity strategy, though a version using a different injection system has already been submitted for US approval. A verdict from the Food and Drug Administration is expected before the end of the year.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

Meanwhile, the existing portfolio is gaining regulatory traction. US and European authorities have cleared a high-dose version of Wegovy, with clinical trials showing average weight loss of 20.7 percent. The weekly basal insulin Awiqli also secured US approval, while the rare-disease candidate Etavopivat hit all primary endpoints in a clinical study.

Pill Power and Pricing Pressure

The oral GLP-1 pill is emerging as a key growth driver, already prescribed to more than one million patients worldwide. Eighty percent of those users had never taken a similar medication before, suggesting the drug is expanding the market rather than just cannibalizing Wegovy sales. In the US, Novo Nordisk is pricing the oral product at $149 per month to compete head-on with Eli Lilly’s new obesity drug Foundayo.

That pricing strategy reflects the brutal reality of the American market. Adjusted US revenues fell 11 percent in the quarter, dragged down by an intensifying price war. Overall obesity-segment sales still grew 22 percent, driven by international demand. The Asia-Pacific region posted a particularly strong performance, with sales climbing 22 percent.

Heavy Spending, Heavy Returns

Capital expenditure for 2026 is expected to reach roughly 55 billion kroner, mostly earmarked for production capacity expansion. Research and development spending in the first quarter totaled 22.4 billion kroner. Despite the heavy investment, Novo Nordisk returned 37.7 billion kroner to shareholders through dividends and buybacks in the first three months. A share repurchase program of up to 15 billion kroner has been running since February.

Novo Nordisk at a turning point? This analysis reveals what investors need to know now.

A Stock in Recovery Mode

Investors greeted the results with a rally. The Copenhagen-listed shares jumped as much as 9.2 percent intraday, while the stock closed at €39.09 on German exchanges. Over the past month, the shares have gained roughly 24 percent. Still, the current price remains a long way from the 52-week high of €70.13, and the stock is nursing deep losses on a 12-month view.

CEO Mike Doustdar pointed to international markets as the engine of future growth. The real test comes in the second half of 2026, when the global rollout of the oral weight-loss pill begins in earnest. Whether that launch can bridge the gap between today’s share price and the heights of last year will depend on how quickly the pipeline pivot pays off.

Ad

Novo Nordisk Stock: New Analysis - 7 May

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

en | DK0062498333 | NOVO | boerse | 69287810 |